New solutions and new therapies need new avenues to reach them. The age of cells producing biological compounds has achieved a lot for human medicine, but its means are coming to an end. A step change in technology is required to unleash the potential of molecules we didn’t dream we would discover – or be able to create if we did.
ELEVA is opening this realm of unprecedented therapies with the help of an inconspicuous but incredibly efficient tool: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they virtually invite easy, stable engineering and reliable output.
… we unlock the potential of difficult compounds that have so far failed to get expressed
… we explore unusual opportunities in other promising fields
We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.
Eleva’s management is driven by making unprecedented and much-needed therapies happen. With our moss-based platform, we are going to translate the features of this ancient plant into the therapies of tomorrow.
Eleva is fortunate to be able to tap into world-class expertise. We deeply value the guidance given by the following specialists:
Chair of Board
Co-Chair of Board
Member of the Board
Member of the Board
Member of the Board
Member of the Board
Eleva’s company values ensure that relationships with partners and employees are guided by reliability and respect. Quality is the prime goal throughout the company. Our guidelines are continuously reviewed.
Our success is based on our highly motivated staff. We have zero tolerance for discrimination of employees on the grounds of their sexual orientation, sex, ethnicity, religion, family status, age, or disability. We provide a safe workplace as well as continuous training and respect of privacy for every staff member.
We know you would love being part of a highly motivated team passionate about making unprecedented therapies available to patients.
Unfortunately, we have no vacancies at this point in time.
In silent mourning we bid farewell to one of our company founders and shareholders Prof. Dr. Gunther Neuhaus. He passed away on July 10, 2021 at the age of 67.
Gunther Neuhaus was born in Linz in 1953. He studied biology at the University of Salzburg and graduated with a doctorate in 1980. This was followed by a habilitation at the Swiss Federal Institute of Technology in Zurich. In 1995, Gunther Neuhaus became Professor of Cell Biology at the University of Freiburg. He headed the Centre for Applied Biosciences and was elected prorector for research.
Gunther Neuhaus was well known as an outstanding scientist. He was also instrumental in developing the moss bioreactor platform by co-founding the Greenovation Biotech GmbH in 1999. Thanks to his commitment and constant support, Eleva is on the way to develop therapeutic proteins for human diseases with the potential to improve the lives of underserved patients. We will miss and remember Gunther as a warm-hearted colleague, a friend and a founder. Our heartfelt condolences go out to his family.